A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT05365035
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Myelodysplastic Syndromes
- Myeloproliferative Chronic Myelomonocytic Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cladribine — DRUGGiven by Vein (IV)
- Cytarabine — DRUGGiven under the skin; subcutaneous injection (SQ)
- Venetoclax — DRUGGiven by PO
- Azacitidine — DRUGGiven by IV or subcutaneous injection (SQ)
Study Details
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
Key Dates
- Start date
- Sep 23, 2022
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: cladribine, cytarabine, venetoclax, and azacitidineParticipants will receive cladribine, cytarabine, and venetoclax for 2 cycles and then azacitidine and venetoclax for 2 cycles. Participants will repeat this pattern of 2 cycles each for up to a total of 18
Primary Outcome Measure
To establish the overall survival (OS). [ Time Frame: through study completion, an average of 1 year ]
Central Contacts
- Guillermo Bravo, MD(713) 794-3604
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Guillermo Bravo, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationPHASE1 · Recruiting · Institut de Recherches Internationales Servier · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesPHASE1 · Recruiting · Orca Biosystems, Inc. · Duarte, California
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)PHASE2 · Enrolling By Invitation · Taiho Oncology, Inc. · Fountain Valley, California